脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究*

doi:10.3969/j.issn.1672-5069.2020.02.025

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (2): 248-251.doi: 10.3969/j.issn.1672-5069.2020.02.025

脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究^*

阿思根, 夏医君, 武慧军, 薛荣泉, 辛瑞强, 白斯古楞, 赵德芳

010010 呼和浩特市内蒙古自治区人民医院肝胆胰脾外科(阿思根,夏医君,武慧军,薛荣泉,辛瑞强);通辽市医院普外科(白斯古楞);内蒙古医科大学第一附属医院肝胆外科(赵德芳)

收稿日期:2019-04-01 出版日期:2020-03-10 发布日期:2020-04-20
通讯作者: 赵德芳,E-mail:603698904@qq.com
作者简介:阿思根,男,35岁,硕士研究生,主治医师
基金资助:
内蒙古自治区自然科学基金资助项目[编号:2017MS(LH)0845]

Efficacy of laparoscopic portal-azygos vein devascularization and splenectomy in treatment of patients with cirrhotic portal hypertension

A Sigen, Xia Yijun, Wu Huijun, et al

Department of Hepatobiliary,Pancreatic and Splenic Surgery,Inner Mongolia People’s Hospital, Hohhot 010010,Inner Mongolia Autonomous Region, China

Received:2019-04-01 Online:2020-03-10 Published:2020-04-20

摘要/Abstract

摘要： 目的研究腹腔镜门奇静脉断流术联合脾切除术治疗肝硬化门脉高压症合并巨脾患者的效果。方法 2016年12月～2018年12月我院收治的86例肝硬化并发门脉高压症合并巨脾患者被分为两组,每组43例,其中对照组行开腹,而观察组实施腹腔镜下门奇静脉断流术联合脾切除术。结果观察组术中出血量为(180.8±23.1)ml,显著少于对照组的【(286.4±35.7)ml,P<0.05】,术后住院日为(6.0±1.3)d,显著短于对照组的【(8.6±1.5)d,P<0.05】;观察组术后7 d外周血WBC为(8.9±1.4)×10⁹/L,PLC为(132.0±28.9)×10⁹/L,对照组分别为(7.2±1.8)×10⁹/L,PLC为(125.6±30.3)×10⁹/L,均较术前显著升高(P<0.05);观察组术后门静脉直径为(1.2±0.1)cm,血流量为(911.7±261.7)ml/min,对照组分别为(1.2±0.2)cm,血流量为(888.5±191.5)ml/min,均较术前显著缩小或下降(P<0.05);观察组术后并发症发生率为9.3%,显著低于对照组的37.2%(P＜0.05)。结论腹腔镜下门奇静脉断流术联合脾切除术治疗肝硬化门脉高压症合并巨脾患者临床疗效确切,创伤小,术后并发症发生率低,恢复快。

关键词: 肝硬化, 门脉高压症, 门奇静脉断流术, 脾切除术, 腹腔镜

Abstract: Objective The aim of this study was to investigate the efficacy of laparoscopic portal-azygos vein devascularization and splenectomy in treatment of patients withcirrhotic portal hypertension. Methods 86 patients with cirrhotic portal hypertension complicated with megaspleen were enrolled in our hospital between December 2016 and December 2018, and 43 patients underwent open and other 43 underwentlaparoscopic portal-azygos vein devascularization and splenectomy. Results The bleeding volume and hospital stay in patients with laparoscopic surgery were(180.8±23.1)ml and (6.0±1.3)d, significantly less or shorter than 【(286.4±35.7)ml and (8.6±1.5)d,P<0.05】 in patients with open surgery; seven days after operation, the white blood cell andplatelet counts in patients with laparoscopic surgery were (8.9±1.4)×10⁹/L and (132.0±28.9)×10⁹/L, and those in patients with open operation were (7.2±1.8)×10⁹/L and (125.6±30.3)×10⁹/L, respectively, all significantly increased as compared to these before operation (P<0.05); the portal vain diameters and blood volume in patients with laparoscopic operationwere(1.2±0.1)cm and (911.7±261.7)ml/min, and those in patients with opensurgery were (1.2±0.2)cm and (888.5±191.5)ml/min, respectively, all significantly narrowed or decreased as compared to these beforeoperation (P<0.05); the post-operational complications in patients with laparoscopic surgery was 9.3%, much lower than 37.2%(P＜0.05) in patients with open operation. Conclusion The application of laparoscopic portal-azygos vein devascularization and splenectomy is efficacious in the treatment of patients with cirrhotic portal hypertension and megaspleen. It might have less trauma, low incidence of complications and quick recovery.

Key words: Liver cirrhosis, Portal hypertension, Laparoscopic portal-azygos vein devascularization, Splenectomy, Laparoscopy

阿思根, 夏医君, 武慧军, 薛荣泉, 辛瑞强, 白斯古楞, 赵德芳. 脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 248-251.

A Sigen, Xia Yijun, Wu Huijun, et al. Efficacy of laparoscopic portal-azygos vein devascularization and splenectomy in treatment of patients with cirrhotic portal hypertension[J]. Journal of Practical Hepatology, 2020, 23(2): 248-251.

参考文献

[1] 杨凯奇, 陈世耀. 特发性门静脉高压症预后及其影响因素. 实用肝脏病杂志, 2018, 21(3):332-335.
[2] Merola J, Fortune BE, Deng Y, et al. Transjugular intrahepatic portosystemic shunt creation for cirrhotic portal hypertension is well tolerated among patients with portal vein thrombosis.Eur J Gastroenterol Hepatol, 2018, 30(6):668-675.
[3] Wang F, Sun Y, Zhang B, et al. Laparoscopic splenectomy and porto-azygos disconnection: clinical research in the treatment of portal hypertension. Open Med, 2015, 10(1):421-424.
[4] Fei Y, Zong G, Chen J, et al. Fast-track protocols in devascularization for cirrhotic portal hypertension. Revista Da Associacao Medica Brasileira, 2015, 61(3):250-257.
[5] Pachta E, Hucke F, Weiss S, et al. Prognostic impact of the BAVENO IV staging system of portal hypertension in patients with cirrhosis and hepatocellular carcinoma. J Hepatol, 2015, 62(17-18):S457-S457.
[6] 中国中西医结合学会消化系统疾病专业委员会. 肝硬化中西医结合诊疗共识. 中国中西医结合消化杂志, 2011, 19(4):277-279.
[7] Su AP, Zhang ZD, Tian BL, et al. Transjugular intrahepatic portosystemic shunt versus open splenectomy and esophagogastric devascularization for portal hypertension with recurrent variceal bleeding. Hepatob Pancreat Dis, 2017, 16(2):169-175.
[8] Lu CL, Cao YJ, Cheng H, et al. Clinical factors that influence the outcome of selective devascularization in the treatment of portal hypertension. Oncotarget, 2016, 7(31):50635-50642.
[9] Sun L, Zhou H, Gu L, et al. Effects of surgical procedures on the occurrence and devolopment of postoperative portal vein thrombosis in patients with cirrhosis complicated by portal hypertension.Int J Surg, 2015, 16(2):31-35.
[10] Chen ZY, Dai CL. Surgical treatment for portal hypertension with hypersplenism. Brit J Surg, 2015, 102(7):717-718.
[11] Duan YF,Li XD,Sun DL, et al. A preliminary study on surgery for hepatocellular carcinoma patients with portal hypertension. Am J Surg, 2015, 210(1):129-133.
[12] 王羊,王金涛,安东均,等.腹腔镜与开腹脾切除加门奇静脉断流术治疗门静脉高压症复发性上消化道出血疗效比较.中华肝胆外科杂志,2018,24(6):386-389.
[13] Yamamoto H, Naoki Y, Okano A, et al. Laparoscopic splenectomy for patients with liver cirrhosis: Improvement of liver function in patients with Child-Pugh class B. Surgery, 2015, 158(6):1538-1544.
[14] Wereszczynka-Siemiatkowska U, Swidnicka-Siergiejko A, Siemiatkowski A, et al. Endothelin 1 and transforming growth factor-β1 correlate with liver function and portal pressure in cirrhotic patients. Cytokine, 2015, 76(2):144-151.
[15] Kawanaka H, Akahoshi T, Kinjo N, et al. Laparoscopic splenectomy with technical standardization and selection criteria for standard or hand-assisted approach in 390 patients with liver cirrhosis and portal hypertension. J Am Coll Surgeons, 2015, 221(2):354-366.
[16] Bayraktar B,Bayraktar O,Ozemir IA, et al. Comparison of two minimal invasive techniques of splenectomy: Standard laparoscopy versus transumbilical multiport single-site laparoscopy with conventional instruments. J Minim Access Surg, 2015, 11(2):143-148.
[17] Yin XY, Lu MD, Huang JF, et al. Color Doppler velocity profile assessment of portal hemodynamics in cirrhotic patients with portal hypertension: correlation with esophageal variceal bleeding. J Clin Ultrasound, 2015, 29(1):7-13.
[18] Al-raimi K,Zheng SS . Postoperative outcomes after open splenectomy versus laparoscopic splenectomy in cirrhotic patients: a meta-analysis. Hepatob Pancreat Dis, 2016, 15(1):14-20.
[19] Feng S,Qiu Y,Li X, et al. Laparoscopic versus open splenectomy in children: a systematic review and meta-analysis. Pediatr Surg Int, 2016, 32(3):253-259.
[20] 曾道炳, 张纯, 邸亮, 等. 脾切除联合门奇静脉断流术对肝硬化合并门静脉高压症患者近远期营养状况的影响. 中华肝胆外科杂志, 2017, 23(7):437-440.

脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究^*

Efficacy of laparoscopic portal-azygos vein devascularization and splenectomy in treatment of patients with cirrhotic portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张玉玲, 周瑾, 董宏伟. 超声点定量弹性成像技术对AIH和PBC患者肝纤维化诊断价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 231-235.
[2]	贾娇, 王芳, 张波, 武琼. 熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 240-243.
[3]	张惠勇, 吴秀欣, 徐成润. 特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 244-247.
[4]	胡星, 孟繁坤, 韩晶, 张旭辉. 应用超声心动图评估肝硬化患者心脏结构和功能临床价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 252-255.
[5]	邢乐康, 邓永东, 姚立琼, 金凤玲. 乙型肝炎肝硬化患者肠道菌群变化研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 256-259.
[6]	毕洁领, 刘美宏, 宋国庆. Rouviere沟引导定向联合胆囊后三角入路腹腔镜胆囊切除术治疗胆囊良性疾病研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 288-291.
[7]	马曙涛, 闫军. 不同手术入路腹腔镜胆囊切除术临床疗效及安全性研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 292-295.
[8]	徐小元. 解读肝硬化诊治指南难点与新颖之处[J]. 实用肝脏病杂志, 2020, 23(1): 4-6.
[9]	杨晓玲, 张素梅. SGA、MNA和NRS2002评估失代偿期肝硬化患者营养状态应用价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 70-73.
[10]	王晶晶, 李春涛, 周卫真. 失代偿期乙型肝炎肝硬化患者尿液视黄醇结合蛋白水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 74-77.
[11]	杨慧玲, 刘小静, 何英利, 杜粉静, 叶峰. 失代偿期乙型肝炎肝硬化患者发生医院感染临床特点及危险因素分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 78-81.
[12]	赵平, 黎涛, 谢吉良, 郑波. 早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 82-85.
[13]	张冰, 解学军. 酒精性肝硬化患者血CTLA-4和PNPLA3基因多态性及其临床意义分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 86-89.
[14]	周帅, 张剑权, 吕明. 完全腹腔镜手术治疗成人先天性胆总管囊肿患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 118-121.
[15]	钱国武, 崔广莹, 宋展, 吕柯, 刘驰, 孙万日. 腹腔镜规则性肝段或肝叶切除治疗复杂性肝内胆管结石患者血浆皮质醇和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 122-125.